Every question you ask can be matched with a suitable answer
Leave me a message
We take every suggestion of yours seriously
Wechat
Tan Xiaojun
·Senior reproductive medicine expert
·Postdoctoral fellow at Peking University
·PhD candidate at Xiangya School of Medicine, Central South
University
·Master’s tutor at Central South University
· Master's degree candidate in reproductive
medicine at the University of South China
· Professional training at Huazhong University
of Science and Technology and Tongji
Hospital Reproductive Center
Expertise:
diagnosis and treatment of infertility, first/second/third generation IVF (including
egg/sperm donation), microsperm retrieval, embryo freezing and resuscitation, artificial
insemination (including husband's sperm and sperm donation), paternity testing, chromosomal
disease
diagnosis, high-throughput gene sequencing, endometrial receptivity gene testing and other
clinical
technology applications. Many of these technologies are at the leading level both domestically
and
internationally.
Is it necessary to go overseas for the third generation test tube for the elderly? Overseas third generation test tube, elderly test tube baby, PGT-A screening, overseas test tube process, pregnancy preparation scheme for the elderly, chromosome abnormality screening, cross-border assisted reproduction.
Is it necessary to go overseas to do three generations of test tubes for the elderly? Six judgment points help you see clearly: medical needs or decision-making anxiety.
First, let's get the question straight: What do you mean "necessary"?
When many people are searching for "Is it necessary to go overseas for the third generation of test tubes at an advanced age", what they really want to ask is not "Can you do it", but three other more essential questions:
First, with the age, the chances of self-conception and routine test tubes have dropped significantly;
Second, what can and cannot be solved by the so-called three-generation test tube;
Third, is going overseas to improve medical matching, or is it just because of information anxiety, time anxiety and comparative anxiety?
From the first-principles point of view, the core of this problem is not the word "overseas" or the word "old age", but: * * Your fertility disorder is mainly stuck in the number of eggs, egg quality, embryo chromosomes, uterine environment, or time window. * * If the question itself is not clear, jump directly to "Do you want to go abroad for three generations", and the decision will often be biased.
It is generally believed in medicine that women's fertility will decline with age, especially after the age of 35; According to ASRM data, the single-cycle chance of natural pregnancy for 40-year-old women is less than 5%, and the risk of aneuploidy and abortion will increase with age. ASRM also pointed out that people aged 35 and over who have failed to conceive for six months should usually enter the reproductive specialist assessment instead of waiting passively.
Second, which elderly people need to seriously consider the third generation of test tubes, rather than just entangled in "the sea is not overseas"?
Not all elderly pregnant people have to go directly to overseas third-generation test tubes. To be more precise, old age itself is a risk factor, but it does not automatically mean that "you must go overseas for three generations".
From the clinical logic point of view, the following groups of people are more worthy of focusing on the evaluation of the third generation test tube path:
First, people who are older and have spent more time preparing for pregnancy. For example, if you are over 38 years old, you have been pregnant naturally for a long time, or you have not been pregnant after ovulation promotion and artificial insemination. The core problem of this kind of people is often not "insufficient efforts", but the time cost is getting higher and higher. ASRM pointed out that increasing age will correspond to a decrease in pregnancy rate, an increase in abortion rate and an increase in the risk of chromosomal abnormalities in embryos.
Second, people who have repeated embryo abortion, repeated abortion or repeated transplant failure. According to the educational data of patients with ASRM, a considerable part of early abortion is related to chromosomal abnormalities in embryos, and the risk of abortion caused by genetic abnormalities will increase significantly with age, which can exceed 50% over 40 years old. This means that some problems of "being pregnant but not staying" are not entirely in the uterus, but may be at the embryonic level.
Third, there are people whose husband and wife have a clear genetic risk. In such cases, the value of three generations of test tubes is often more clear. Because there is not only one PGT:
PGT-A is mainly used to identify whether there is abnormal chromosome number in embryos.
PGT-M is used for risk screening of single-gene genetic diseases;
PGT-SR is used for chromosome rearrangement.
In other words, many people are used to generally understanding the "third generation test tube" as "screening embryos", which is actually not accurate enough. Whether it is really suitable depends on the indications.
Fourth, the ovarian reserve is declining and the number of eggs obtained is limited, but it is hoped that the number of people who have invalid transplants will be reduced as much as possible. The contradiction of this kind of population lies in: there are few embryos, and the screening value may exist; However, there are few embryos, and the number of transplantable embryos may be further reduced after PGT. Therefore, this is not a simple question of "the older you get, the more you should do it", but a typical individualized question.
What can the third and third generation test tubes solve? Don't think of it as an "age reverser"
Many contents make the third generation test tube too magical, which is inaccurate.
PGT-A in the third generation of test tubes is essentially an embryo screening tool, which does not make the eggs younger or the embryos better. What it can do is: identify some embryos with abnormal chromosome number as far as possible among the embryos that have been formed, help the clinic to optimize the transplantation order under certain conditions, or reduce the risk of abortion caused by chromosome abnormality. ESHRE data also listed old age, repeated implantation failure, serious male factors and repeated abortion as the common indications of PGT-A.
On the other hand, PGT-A also has a very clear boundary. The ASRM 2024 Committee pointed out that the use of PGT-A is increasing in the United States, but its value as a routine screening method is still unclear, and the existing research results are inconsistent. The British HFEA also made it clear that there is no evidence of randomized controlled trials to prove that PGT-A in blastocyst stage can improve the chance of live birth for most people receiving IVF. As a selection tool, it often reduces the number of embryos available for transplantation. At present, HFEA still gives a gray rating with insufficient evidence for the matter of "increasing the live birth rate of older women".
What does this mean?
It means that the third generation test tube is not a universal upgrade package. It is more suitable for people with specific medical purposes, and is not suitable for being regarded as a "standard action" for all elderly pregnant women. If a person has few embryos and relies too much on PGT-A, the result may be that there are no transplantable embryos after screening, which will increase time and economic consumption.
Fourth, the common questions should be clarified first: Is it really "better" to do three generations of test tubes overseas?
You can't answer this question in general, you can only take it apart.
1) Is overseas necessarily more suitable for the elderly than at home?
Not necessarily.
"Overseas" is not a medical conclusion, but a geographical label. What really affects the outcome is the laboratory level, ovulation promotion strategy, embryo culture ability, genetic testing norms, transplantation strategy and case matching, not the passport itself. According to the national summary data of ART in the United States in 2022 published by CDC, the average age of patients receiving ART treatment is 36.3 years old, and about 37.5% of them have delivered live births in all cycles, indicating that assisted reproduction itself is indeed a mature medical path, but the results are still affected by age, etiology and case structure, and will not be automatically reversed because of "cross-border".
2) If you are old, you should do it directly for three generations. Don't you need to evaluate it first?
This premise is inherently problematic.
Old age is only an increase in risk, not a pass without assessment. Even if the age is the same, patient A may have embryonic chromosome problems, patient B may have endometrial receptivity problems, patient C may have serious sperm factors in the man, and patient D may even have untreated hydrosalpinx. Different underlying problems have completely different paths.
3) If PGT-A is done, can it avoid miscarriage?
I can't.
HFEA clearly points out that PGT-A may reduce the abortion probability of some patients to some extent, but it cannot eliminate the risk of abortion, because the causes of abortion not only come from aneuploidy of embryos, but also may involve maternal factors, immunity, uterine anatomy, endocrine and other problems.
4) What are the core benefits of going overseas at an advanced age?
From the perspective of decision-making, there are three main types of possible benefits:
First, enter the treatment rhythm faster and reduce waiting;
Second, some areas are more mature or flexible in PGT, egg donation and medical treatment arrangement;
Third, it is convenient to make inspection, ovulation promotion, egg retrieval, screening, embryo freezing and transplantation into a clearer project management process.
However, the preconditions for the establishment of these benefits are: compliance of local institutions, case matching, smooth language communication and complete genetic counseling. Otherwise, "overseas" may change from an advantage to an extra variable. This judgment is a logical deduction, and the confidence is moderate, because the specific benefits are highly dependent on the destination regulations and institutional capabilities.
5) What are the main risks of going overseas at an advanced age?
The main risk is not as simple as "going abroad", but four aspects:
First, time and cost increase;
Second, it is more difficult to connect cross-border continuous treatment;
Third, it is not easy to verify the real laboratory ability and indications of the institution;
Fourth, it is easy to put psychological expectations into the technology itself, ignoring the hard constraints of age and egg quality.
5. If you decide to seriously consider it, how do you usually get to the overseas third-generation test tubes?
From the process point of view, if the elderly people consider the third generation of overseas test tubes, they usually do not "go and do it", but at least go through the following links.
First, the basic assessment. Including the woman's age, AMH, basal sinus follicle, menstrual history, previous pregnancy outcome, abortion history, uterine evaluation, infection screening, as well as male semen analysis and genetic examination when necessary. The purpose of this stage is to judge whether the problem is focused on ovary, embryo, uterus or genetic factors.
The second step is to make a plan. The doctor will estimate the ovulation promotion plan according to the age and ovarian response, and judge whether to strive for more embryos first or enter the transplant as soon as possible; Medical indications of PGT-A, PGT-M or PGT-SR will also be evaluated.
The third step is ovulation promotion, egg retrieval, fertilization and blastocyst culture. If the embryo develops to blastocyst stage, some cases will enter biopsy and PGT. It should be noted that whether you can enter the screening does not depend on your wishes, but on whether there are enough detectable embryos. This is the common difficulty of elderly patients: it is not "screening or not", but "whether there are embryos to screen". This is a common clinical reality with high confidence.
The fourth step is the interpretation of the results and the arrangement of transplantation. After getting PGT results, it is not the end of seeing "normal embryos", but also the uterine environment, endometrial preparation, hormone status and whether there are factors affecting implantation and pregnancy maintenance. PGT-A only screened out the relative priority sequence at the chromosome level, which does not mean that the pregnancy outcome has been locked.
The fifth step is follow-up after pregnancy. ESHRE data also suggest that even with PGT-A, prenatal screening and prenatal diagnosis are still valuable when necessary. In other words, PGT is not a substitute for pregnancy management, but a part of pre-screening.
Sixth, finally give a conclusion: Is it necessary to go overseas for three generations of test tubes when you are pregnant?
The conclusion is not as simple as "yes" or "no", but "it is clearly necessary for some people, and it is only premature for others to upgrade".
If you are in the following situations, it is usually more necessary to evaluate the third generation test tubes overseas:
Has been over 35 years old and failed to prepare for pregnancy for a long time;
Over 38 years old and don't want to continue to consume time windows;
Repeated abortion and repeated transplant failure;
One of the spouses has a clear risk of genetic disease or chromosomal abnormality;
It is hoped that a more systematic reproductive evaluation and treatment arrangement will be completed in a short period.
This kind of people take the "third generation test tube" as the key option, which has strong logic and high confidence.
However, if you are just "age anxiety", the examination is not complete, the cause is not stratified, the expectation of embryo number is not clear, and even the basic reproductive assessment has not been completed, then it is not necessarily a better solution to jump directly to "going overseas for the third generation". Because the key to medical decision-making is never to choose the country first, but to identify the problem first. The underlying logic of this judgment is very clear and the confidence is high.
The truly mature decision-making order should be: first judge whether it needs three generations, and then judge whether it is necessary to go overseas; First look at medical indications, then look at regional selection; Look at your own time window first, and then look at propaganda.
summary
Going abroad for the third generation of test tubes when you are pregnant at an advanced age is not "the sooner you go abroad, the better", but "the earlier you do it, the more important it is to evaluate it".
The value of the third generation test tube is mainly reflected in embryo screening and risk management under specific indications; It can't reverse ovarian age, and it can't promise live birth results. It may be a more targeted path for people with real age pressure, repeated failure history or genetic risk; For people who just haven't completed the systematic assessment, it is often more important to find out the problem first than to rush across the border.
Common aliases:Kyrgyzstan Tulip Reproductive Center, Tulip IVF, Tulip Reproductive Center, Tulip Hospital, Kyrgyz Tulip Reproductive Center, Kyrgyz Tulip Hospital
